Neubase Therapeutics Stock Price Prediction
| NBSE Stock | USD 0.42 0.01 2.33% |
Oversold Vs Overbought
26
Oversold | Overbought |
NeuBase Therapeutics stock price prediction is an act of determining the future value of NeuBase Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of NeuBase Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of NeuBase Therapeutics and does not consider all of the tangible or intangible factors available from NeuBase Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with NeuBase Therapeutics, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting NeuBase Therapeutics' stock price prediction:Wall Street Target Price 140 | EPS Estimate Current Quarter (1.82) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of NeuBase Therapeutics based on different types of headlines from major news networks to social media. The NeuBase stock price prediction module provides an analysis of price elasticity to changes in media outlook on NeuBase Therapeutics over a specific investment horizon. Using NeuBase Therapeutics hype-based prediction, you can estimate the value of NeuBase Therapeutics from the perspective of NeuBase Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards NeuBase Therapeutics using NeuBase Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards NeuBase using crowd psychology based on the activity and movement of NeuBase Therapeutics' stock price.
NeuBase Therapeutics Implied Volatility | 0.0 |
NeuBase Therapeutics' implied volatility exposes the market's sentiment of NeuBase Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if NeuBase Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that NeuBase Therapeutics stock will not fluctuate a lot when NeuBase Therapeutics' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in NeuBase Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in NeuBase Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying NeuBase because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
NeuBase Therapeutics after-hype prediction price | USD 0.42 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
NeuBase |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of NeuBase Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
NeuBase Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of NeuBase Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in NeuBase Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of NeuBase Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
NeuBase Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting NeuBase Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on NeuBase Therapeutics' historical news coverage. NeuBase Therapeutics' after-hype downside and upside margins for the prediction period are 0.02 and 8.86, respectively. We have considered NeuBase Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
NeuBase Therapeutics is not too volatile at this time. Analysis and calculation of next after-hype price of NeuBase Therapeutics is based on 3 months time horizon.
NeuBase Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as NeuBase Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeuBase Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with NeuBase Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.18 | 8.51 | 0.00 | 0.09 | 4 Events / Month | 12 Events / Month | In about 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.42 | 0.42 | 0.00 |
|
NeuBase Therapeutics Hype Timeline
NeuBase Therapeutics is now traded for 0.42. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.09. NeuBase is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is now at -0.18%. %. The volatility of related hype on NeuBase Therapeutics is about 1736.73%, with the expected price after the next announcement by competition of 0.51. About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.18. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeuBase Therapeutics recorded a loss per share of 18.6. The entity last dividend was issued on the 4th of February 2019. The firm had 1:20 split on the 15th of June 2023. Given the investment horizon of 90 days the next projected press release will be in about 4 days. Check out NeuBase Therapeutics Basic Forecasting Models to cross-verify your projections.NeuBase Therapeutics Related Hype Analysis
Having access to credible news sources related to NeuBase Therapeutics' direct competition is more important than ever and may enhance your ability to predict NeuBase Therapeutics' future price movements. Getting to know how NeuBase Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how NeuBase Therapeutics may potentially react to the hype associated with one of its peers.
NeuBase Therapeutics Additional Predictive Modules
Most predictive techniques to examine NeuBase price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for NeuBase using various technical indicators. When you analyze NeuBase charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About NeuBase Therapeutics Predictive Indicators
The successful prediction of NeuBase Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as NeuBase Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of NeuBase Therapeutics based on analysis of NeuBase Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to NeuBase Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NeuBase Therapeutics's related companies. | 2011 | 2023 | 2024 (projected) | Dividend Yield | 0.0634 | 0.0142 | 0.0135 | Price To Sales Ratio | 2.16 | 1.95 | 1.85 |
Story Coverage note for NeuBase Therapeutics
The number of cover stories for NeuBase Therapeutics depends on current market conditions and NeuBase Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that NeuBase Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about NeuBase Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
NeuBase Therapeutics Short Properties
NeuBase Therapeutics' future price predictability will typically decrease when NeuBase Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of NeuBase Therapeutics often depends not only on the future outlook of the potential NeuBase Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. NeuBase Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.6 M | |
| Cash And Short Term Investments | 23.2 M |
Check out NeuBase Therapeutics Basic Forecasting Models to cross-verify your projections. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.